Accordingly, Western blot analysis showed that only JQ1 and not venetoclax reduced phosphorylation of ERK1/2 and AKT, potentially explaining the synergy of drugs in impairing CLL survival from a regulatory point of view (Figure 2G,H). Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.